TLX1N Stock Chart & Stats
$302.55
$0.00(0.00%)
At close: 4:00 PM EDT
$302.55
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$302.55 - $302.55
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$66.53B
Enterprise Value$4.28K
Total Cash (Recent Filing)$212.74M
Total Debt (Recent Filing)$699.77M
Price to Earnings (P/E)―
Beta-0.66
Next Earnings
Aug 20, 2026EPS Estimate
0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding339,784,300
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio2.81
Price to Book (P/B)6.08
Price to Sales (P/S)3.04
P/FCF Ratio-44.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$307.37Price Target Upside1.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)0.39
Revenue Forecast (FY)$11.98B
Bulls Say, Bears Say
Bulls Say
Sustained High Revenue Growth And Clear FY2026 GuidanceConsistent multi-year double-digit growth and explicit FY2026 guidance demonstrate durable commercial traction and scaling of sales operations. This level of top-line expansion improves operating leverage, supports ongoing reinvestment in pipeline and infrastructure, and underpins a higher base for future margin expansion and cash generation.
High-margin, Cash-generative Precision Medicine FranchiseA core business that produces the vast majority of gross margin provides a durable profit engine to fund growth. Strong Precision Medicine margins and EBITDA convert revenue into cash, enabling self-funding of R&D and manufacturing buildout while cushioning group profitability against lower-margin exposures.
Deep Late-stage Pipeline And Stepped-up R&D InvestmentSubstantial capital allocation to R&D and pivotal-stage programs signals a structural shift toward therapeutic commercialization. Combined with manufacturing investment, this increases the probability of future high-margin product launches, expands addressable markets, and creates longer-term value drivers beyond the current diagnostic franchise.
Bears Say
Rising Leverage And Elevated Debt LevelsA material step-up in debt relative to equity reduces financial flexibility and increases refinancing and interest-rate exposure. For a company with volatile near-term earnings and continued high R&D spend, elevated leverage heightens the risk that growth investments will require external funding or constrain capital allocation if cash generation falters.
Reversal To Negative Operating And Free Cash Flow In 2025A shift from positive to negative cash conversion signals worsening working capital, higher spending, or weaker cash margins. Persistently negative free cash flow would strain liquidity while the company continues heavy R&D and manufacturing spending, potentially forcing dilutive financing or curtailed investment into strategic programs.
Regulatory Setbacks And Required Resubmissions For Key ProgramsFailed or delayed approvals for pivotal therapeutic candidates create structural execution risk: approvals drive future product revenue and validate the pipeline. Resubmissions extend timelines and increase development costs, delaying potential high-margin therapeutic revenue and the payback on elevated R&D and manufacturing investments.
Telix Pharmaceuticals News
TLX1N FAQ
What was Telix Pharmaceuticals Ltd.’s price range in the past 12 months?
Telix Pharmaceuticals Ltd. lowest stock price was $302.55 and its highest was $302.55 in the past 12 months.
What is Telix Pharmaceuticals Ltd.’s market cap?
Telix Pharmaceuticals Ltd.’s market cap is $66.53B.
When is Telix Pharmaceuticals Ltd.’s upcoming earnings report date?
Telix Pharmaceuticals Ltd.’s upcoming earnings report date is Aug 20, 2026 which is in 9 days.
How were Telix Pharmaceuticals Ltd.’s earnings last quarter?
Telix Pharmaceuticals Ltd. released its earnings results on Feb 19, 2026. The company reported -$0.206 earnings per share for the quarter, missing the consensus estimate of $0.686 by -$0.891.
Is Telix Pharmaceuticals Ltd. overvalued?
According to Wall Street analysts Telix Pharmaceuticals Ltd.’s price is currently Undervalued.
Does Telix Pharmaceuticals Ltd. pay dividends?
Telix Pharmaceuticals Ltd. does not currently pay dividends.
What is Telix Pharmaceuticals Ltd.’s EPS estimate?
Telix Pharmaceuticals Ltd.’s EPS estimate is 0.34.
How many shares outstanding does Telix Pharmaceuticals Ltd. have?
Telix Pharmaceuticals Ltd. has 339,784,300 shares outstanding.
What happened to Telix Pharmaceuticals Ltd.’s price movement after its last earnings report?
Telix Pharmaceuticals Ltd. reported an EPS of -$0.206 in its last earnings report, missing expectations of $0.686. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Telix Pharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in MX:TLX1N
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Telix Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$307.37 (1.59% Upside)
$307.37 (1.59% Upside)
Blogger Sentiment
Bullish
MX:TLX1N Sentiment 95%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $1.7M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-25.76%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
25.10%
Trailing 12-Months
Company Description
Telix Pharmaceuticals Ltd.
Telix Pharmaceuticals Limited is an Australian-based radiopharmaceutical company dedicated to pioneering molecularly targeted radiation (MTR) products. These innovations are developed for the diagnosis and treatment of various cancers and rare conditions, with its global presence encompassing Australia, Belgium, Japan, Switzerland, and the United States. The company's robust pipeline includes several leading candidates. TLX591-CDx is engineered for the diagnosis and treatment of metastatic castrate-resistant prostate cancer, while TLX66-CDx is designed for bone marrow conditioning and rare diseases. In advanced clinical development, TLX250-CDx is in Phase III trials for renal (kidney) cancer diagnosis and treatment, alongside TLX250 in Phase II for the same indication. TLX591 is also undergoing Phase III trials for metastatic castrate-resistant prostate cancer. For glioblastoma (brain cancer), TLX101 and TLX101-CDx are currently in Phase I/II studies, and TLX66 is in Phase I/IIa trials for bone marrow conditioning and rare diseases. Beyond these flagship programs, Telix is actively developing TLX592, a targeted alpha therapy candidate for prostate cancer. Its portfolio also features TLX591-Sx, a versatile PET tracer capable of both PET and fluorescent (optical) imaging, and TLX599-CDx, an investigational prostate cancer imaging agent utilizing single-photon emission computed tomography (SPECT). Strategic collaborations are integral to Telix's operations. This includes a significant license and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited for MTR product development, a scientific and clinical research alliance with Mauna Kea Technologies, and a strategic collaboration agreement with Lightpoint Medical, Ltd. Founded in 2015, the company's headquarters are located in North Melbourne, Australia.
TLX1N Stock 12 Month Forecast
Average Price Target
$307.37
▲(1.59% Upside)